The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 25, 2020

Filed:

Jul. 21, 2015
Applicants:

Novartis Ag, Basel, CH;

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Inventors:

Jennifer Brogdon, Sudbury, MA (US);

Hilmar Erhard Ebersbach, Basel, CH;

Saar Gill, Philadelphia, PA (US);

David Glass, Cambridge, MA (US);

Julia Jascur, Basel, CH;

Saad Kenderian, Philadelphia, PA (US);

Joan Mannick, Cambridge, MA (US);

Michael C. Milone, Cherry Hill, NJ (US);

Leon Murphy, Cambridge, MA (US);

Celeste Richardson, Cambridge, MA (US);

Reshma Singh, Cambridge, MA (US);

Lai Wei, Shanghai, CN;

Qilong Wu, Shanghai, CN;

Qiumei Yang, Shanghai, CN;

Jiquan Zhang, Shanghai, CN;

Assignees:

Novartis AG, Basel, CH;

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); A61K 31/7068 (2006.01); C07K 14/705 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 31/7068 (2013.01); A61K 45/06 (2013.01); C07K 14/7051 (2013.01); C07K 14/70578 (2013.01); C07K 16/2851 (2013.01); A61K 2039/5156 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01);
Abstract

The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.


Find Patent Forward Citations

Loading…